Frequently Asked Questions (FAQ)
1. What is the cost basis for PPD's distribution of Furiex shares?
Please read the following PPD Stockholder Tax Basis Information.
2. Does Furiex have a direct stock purchase plan or a dividend reinvestment program (DRIP)?
No, Furiex does not have a direct stock purchase plan or a dividend reinvestment program.
3. Who is the transfer agent for Furiex?
American Stock Transfer & Trust Company, located at 6201 15th Ave., Brooklyn, NY 11219. The toll-free number is +1 800 937 5449. The worldwide telephone number is +1 718 921 8124.
4. What is a direct registration system (DRS)?
Furiex's common stock is direct registration system (DRS)-eligible. DRS is a method of recording shares of stock in book-entry form through Furiex's transfer agent, American Stock Transfer & Trust Company. This eliminates the need for physical share certificates.
5. Who are the independent auditors for Furiex?
Deloitte & Touche LLP (Raleigh, N.C.)
6. Who are Furiex’s principal officers?
Please see the Principal Officers page.
7. Who are Furiex’s Board of Directors?
Please see the Board of Directors page.
8. What is Furiex’s business strategy?
Furiex’s strategy is to leverage its drug development experience to in-license and develop novel drug candidates. We seek collaborations on compounds addressing medical conditions with large markets and unmet needs. Key elements of Furiex’s strategy include:
- Advancing the clinical development of its current drug candidates
- In-licensing or acquiring additional promising compounds
- Developing strong partnerships in the pharmaceutical and biotechnology sectors
9. What is Furiex’s product pipeline?
Please see the Global Pipeline page.
10. Whom do I contact for information regarding Furiex?
Sailash Patel
Vice President, Strategic Development
Furiex Pharmaceuticals, Inc.
3900 Paramount Parkway, Suite 150
Morrisville, North Carolina 27560
United States
Sailash.Patel@furiex.com
+1 919 456 7814